Article info
PDFA difficult case
Hypothyroid ataxia complicating monoclonal antibody therapy
- Correspondence to Abdul Badran, University of Cambridge, Churchill College, Storey’s Way, Cambridge, CB3 0DS, UK; arb94{at}cam.ac.uk
Citation
Hypothyroid ataxia complicating monoclonal antibody therapy
Publication history
- Accepted July 14, 2017
- First published August 4, 2017.
Online issue publication
February 26, 2018
Article Versions
- Previous version (15 November 2017).
- Previous version (15 November 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Other content recommended for you
- Guillain-Barré syndrome and checkpoint inhibitor therapy: insights from pharmacovigilance data
- Checkpoint inhibitors in head and neck cancer: current knowledge and perspectives
- Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
- Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort
- Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience
- Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
- Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records
- Cardiotoxicity of immune checkpoint inhibitors
- Investigating hypothyroidism